A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Diabetes-cell-therapy-Diatranz-Otsuka-Limited (Primary)
- Indications Type 1 diabetes mellitus
- Focus First in man; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 02 Sep 2024 New trial record